Blood-brain barrier, cytotoxic chemotherapies and glioblastoma - Sorbonne Université Access content directly
Journal Articles Expert Review of Neurotherapeutics Year : 2016

Blood-brain barrier, cytotoxic chemotherapies and glioblastoma


Introduction: Glioblastomas (GBM) are the most common and aggressive primary malignant brain tumors in adults. The blood brain barrier (BBB) is a major limitation reducing efficacy of anti-cancer drugs in the treatment of GBM patients. Areas covered: Virtually all GBM recur after the first-line treatment, at least partly, due to invasive tumor cells protected from chemotherapeutic agents by the intact BBB in the brain adjacent to tumor. The passage through the BBB, taken by antitumor drugs, is poorly and heterogeneously documented in the literature. In this review, we have focused our attention on: (i) the BBB, (ii) the passage of chemotherapeutic agents across the BBB and (iii) the strategies investigated to overcome this barrier. Expert commentary: A better preclinical knowledge of the crossing of the BBB by antitumor drugs will allow optimizing their clinical development, alone or combined with BBB bypassing strategies, towards an increased success rate of clinical trials.
Fichier principal
Vignette du fichier
Drean_2016_Blood-brain.pdf (639.6 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-01414544 , version 1 (12-12-2016)



Antonin Dréan, Lauriane Goldwirt, Maïté Verreault, Michael Canney, Charlotte Schmitt, et al.. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma. Expert Review of Neurotherapeutics, 2016, 16 (11), pp.1285 - 1300. ⟨10.1080/14737175.2016.1202761⟩. ⟨hal-01414544⟩
443 View
2173 Download



Gmail Mastodon Facebook X LinkedIn More